Literature DB >> 18316604

T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model.

Lionel W Hebbard1, Michèle Garlatti, Lawrence J T Young, Robert D Cardiff, Robert G Oshima, Barbara Ranscht.   

Abstract

T-cadherin delineates endothelial, myoepithelial, and ductal epithelial cells in the normal mouse mammary gland, and becomes progressively restricted to the vasculature during mammary tumorigenesis. To test the function of T-cadherin in breast cancer, we inactivated the T-cadherin (Cdh13) gene in mice and evaluated tumor development and pathology after crossing the mutation into the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyV-mT) transgenic model. We report that T-cadherin deficiency limits mammary tumor vascularization and reduces tumor growth. Tumor transplantation experiments confirm the stromal role of T-cadherin in tumorigenesis. In comparison with wild-type MMTV-PyV-mT controls, T-cadherin-deficient tumors are pathologically advanced and metastasize to the lungs. T-cadherin is a suggested binding partner for high molecular weight forms of the circulating, fat-secreted hormone adiponectin. We discern adiponectin in association with the T-cadherin-positive vasculature in the normal and malignant mammary glands and report that this interaction is lost in the T-cadherin null condition. This work establishes a role for T-cadherin in promoting tumor angiogenesis and raises the possibility that vascular T-cadherin-adiponectin association may contribute to the molecular cross-talk between tumor cells and the stromal compartment in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316604      PMCID: PMC2676344          DOI: 10.1158/0008-5472.CAN-07-2953

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Transgenic Polyoma middle-T mice model premalignant mammary disease.

Authors:  J E Maglione; D Moghanaki; L J Young; C K Manner; L G Ellies; S O Joseph; B Nicholson; R D Cardiff; C L MacLeod
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 2.  Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.

Authors:  Takashi Kadowaki; Toshimasa Yamauchi; Naoto Kubota; Kazuo Hara; Kohjiro Ueki; Kazuyuki Tobe
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

3.  Increased expression of H/T-cadherin in tumor-penetrating blood vessels.

Authors:  L Wyder; A Vitaliti; H Schneider; L W Hebbard; D R Moritz; M Wittmer; M Ajmo; R Klemenz
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

4.  Proteomic characterization of human serum proteins associated with the fat-derived hormone adiponectin.

Authors:  Yu Wang; Lance Yi Xu; Karen S L Lam; Gang Lu; Garth J S Cooper; Aimin Xu
Journal:  Proteomics       Date:  2006-07       Impact factor: 3.984

5.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2.

Authors:  Renhai Cao; Ebba Bråkenhielm; Robert Pawliuk; David Wariaro; Mark J Post; Eric Wahlberg; Philippe Leboulch; Yihai Cao
Journal:  Nat Med       Date:  2003-03-31       Impact factor: 53.440

6.  Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.

Authors:  K O Toyooka; S Toyooka; A K Virmani; U G Sathyanarayana; D M Euhus; M Gilcrease; J D Minna; A F Gazdar
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

7.  Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase.

Authors:  Lesley G Ellies; Michael Fishman; Joy Hardison; Jeanine Kleeman; Jeannie E Maglione; Cathyryne K Manner; Robert D Cardiff; Carol L MacLeod
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

8.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Authors:  Elaine Y Lin; Joan G Jones; Ping Li; Liyin Zhu; Kathleen D Whitney; William J Muller; Jeffrey W Pollard
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression.

Authors:  Zhi-yong Huang; YanLi Wu; Nicolé Hedrick; David H Gutmann
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

10.  T-cadherin suppresses angiogenesis in vivo by inhibiting migration of endothelial cells.

Authors:  Kseniya Rubina; Natalia Kalinina; Alexandra Potekhina; Anastasia Efimenko; Ekaterina Semina; Alexei Poliakov; David G Wilkinson; Yelena Parfyonova; Vsevolod Tkachuk
Journal:  Angiogenesis       Date:  2007-05-08       Impact factor: 9.596

View more
  69 in total

Review 1.  Involvement of members of the cadherin superfamily in cancer.

Authors:  Geert Berx; Frans van Roy
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09-23       Impact factor: 10.005

2.  T-cadherin is critical for adiponectin-mediated cardioprotection in mice.

Authors:  Martin S Denzel; Maria-Cecilia Scimia; Philine M Zumstein; Kenneth Walsh; Pilar Ruiz-Lozano; Barbara Ranscht
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

3.  Impact of adiponectin deficiency on pulmonary responses to acute ozone exposure in mice.

Authors:  Ming Zhu; Christopher Hug; David I Kasahara; Richard A Johnston; Alison S Williams; Norah G Verbout; Huiqing Si; Jordan Jastrab; Amit Srivastava; Erin S Williams; Barbara Ranscht; Stephanie A Shore
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-13       Impact factor: 6.914

Review 4.  Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk.

Authors:  Jennifer H Stern; Joseph M Rutkowski; Philipp E Scherer
Journal:  Cell Metab       Date:  2016-05-10       Impact factor: 27.287

Review 5.  Adiponectin as a Potential Therapeutic Target for Prostate Cancer.

Authors:  Hanuma Kumar Karnati; Manas Kumar Panigrahi; Yazhou Li; David Tweedie; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 6.  Adiponectin and breast cancer.

Authors:  Xiuping Chen; Yitao Wang
Journal:  Med Oncol       Date:  2010-07-13       Impact factor: 3.064

7.  Cadherin 13: human cis-regulation and selectively-altered addiction phenotypes and cerebral cortical dopamine in knockout mice.

Authors:  Jana Drgonova; Donna Walther; G Luke Hartstein; Mohammad O Bukhari; Michael H Baumann; Jonathan Katz; Frank Scott Hall; Elizabeth R Arnold; Shaun Flax; Anthony Riley; Olga Rivero-Martin; Klaus-Peter Lesch; Juan Troncoso; Barbara Ranscht; George R Uhl
Journal:  Mol Med       Date:  2016-08-18       Impact factor: 6.354

8.  Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo.

Authors:  Shira Landskroner-Eiger; Binzhi Qian; Eric S Muise; Andrea R Nawrocki; Joel P Berger; Eugene J Fine; Wade Koba; Yingfeng Deng; Jeffrey W Pollard; Philipp E Scherer
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

9.  Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer.

Authors:  Martin S Denzel; Lionel W Hebbard; Gregory Shostak; Lawrence Shapiro; Robert D Cardiff; Barbara Ranscht
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

10.  Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations.

Authors:  Elin Org; Susana Eyheramendy; Peeter Juhanson; Christian Gieger; Peter Lichtner; Norman Klopp; Gudrun Veldre; Angela Döring; Margus Viigimaa; Siim Sõber; Kärt Tomberg; Gertrud Eckstein; Piret Kelgo; Tiina Rebane; Sue Shaw-Hawkins; Philip Howard; Abiodun Onipinla; Richard J Dobson; Stephen J Newhouse; Morris Brown; Anna Dominiczak; John Connell; Nilesh Samani; Martin Farrall; Mark J Caulfield; Patricia B Munroe; Thomas Illig; H-Erich Wichmann; Thomas Meitinger; Maris Laan
Journal:  Hum Mol Genet       Date:  2009-03-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.